| |
|
|
| |
| 投稿时间： 2015-08-11 最后修改时间： 2015-11-12 摘要点击次数: 3715 全文下载次数: 7 |
| |
| 引用本文：王雅楠, 官海静, 刘国恩,等.台湾地区医保药品的采购模式和支付价格[J].中国卫生政策研究,2015,8(12):18-22 |
|
| 王雅楠1, 官海静2, 刘国恩2, 孙利华1 |
1. 沈阳药科大学工商管理学院 辽宁沈阳 110016;
2. 北京大学中国卫生经济研究中心 北京 100080 |
| |
|
| | 摘要:目的:分析台湾地区医保药品在采购和支付方面的做法和经验,为大陆地区推进药品采购模式和支付价格改革提供参考。方法:系统梳理台湾地区在医保药品采购和支付方面的政策文件和相关文献,并与大陆地区药品采购和支付政策进行对比分析。结果:台湾地区医疗机构根据自身用药需求,自主采购药品,采购价格由供需双方直接谈判形成。政府仅对医保药品的价格进行管理,对新药采用国际参考定价办法;原厂药、BA/BE学名药、一般学名药的支付价以国际参考价格为上限,依次降低。药品质量也在医保支付标准考虑之列。此外,药品的支付价格依据采购价格实行动态调整,当二者差值大于30%时,健保署便会调整支付价格以减小二者的差价。结论:台湾地区通过制度设计和调整,较好地统筹了药品采购和补偿两个环节,形成了合理的药品采购价格和支付价格,这些经验可为中国大陆地区完善药品采购和支付政策提供参考。 | |
|
|
关键词:台湾地区 药品采购模式 医保支付价格 药品支付价格
|
| |
| Pharmaceutical procurement and reimbursement schedule in Taiwan |
| WANG Ya-nan1, GUAN Hai-jing2, LIU Guo-en2, SUN Li-hua1 |
1. School of Business Administration, Shenyang Pharmaceutical University, Shenyang Liaoning 110016, China;
2. China Center for Health Economic Research, Peking University, Beijing 100080, China |
| |
|
| | Abstract:Object: The paper aims to analyze Taiwanese experience in pharmaceutical procurement, pharmaceutical benefits and reimbursement schedule, and make references for the Mainland China. Methods: Through reading and analyzing the Taiwanese government policy and the literature published to find out the pharmaceutical procurement measures, different medicines' pricing strategy and its reimbursement mode compared with the Mainland China. Results: Hospitals can purchase medicines based on their own needs, and the purchase price was formed through negotiating with providers and buyers. It has been found that Taiwan only controls the medicines reimbursement prices. The international reference pricing is adopted for new medicines, and the originators, bioequivalence/bioavailability generic medicines and general generics reimbursement prices are very high at international reference prices, and need to be weakened in order to fit the requirements. Moreover, the medicine quality is one of the standards considered in case of making decisions on the reimbursement prices. In addition, the reimbursement price is associated with procurement price. When the spread is larger than 30%, the government will adjust the reimbursement to fill the gap. Conclusions: Through the system design and adjustment, the Taiwanese Government have set up a better procurement and reimbursement co-ordination in the pharmaceutical segment, and formed the reasonable prices for the case. The Taiwanese experience can be taken as a reference for the mainland China to refine its procurement reforms and reimbursement policy. | |
|
|
|
|
